SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A strong quarterly earnings report and ambitious AI-compute expansion outlook are fueling bullish interest, while traders debate the spending plans, valuation, and potential Tesla merger. The large share unlock and profit-taking are tempering enthusiasm, with some traders viewing the added supply as a risk to the post-earnings rally.

Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 is headquartered in New York, NY.

Skydance Corp. - Ordinary Shares - Class B

The distribution and separate trading of long-dated warrants has driven sharp price swings and confusion over whether the share-price drop was mainly a mechanical adjustment or a loss in value. Some holders say the shares and warrants should be considered together, while skeptics point to dilution and the heavy debt from the Warner Bros. Discovery deal.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives expanded Bitcoin treasury and the closing/listing of its SATS preferred offering are fueling attention, with bulls viewing the proceeds as capital for further Bitcoin purchases. The rally is drawing enthusiasm, while skeptics warn that the high dividend burden and potential share issuance could weigh on common shareholders.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention ahead of its earnings report, with traders debating whether the recent selloff reflects pre-report profit-taking or a possible leak; claims of leaked results remain speculation. Some see the pullback as a buying opportunity, while others are wary of further downside and the options-implied move.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly earnings are the dominant focus, with traders watching AI spending guidance and whether the Muse rollout can show traction and justify the investment. Views are split: bulls expect AI momentum to support growth, while bears worry that rising capex, weaker cash flow and a New Mexico privacy ruling could weigh on the stock.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Six Flags is under pressure after Mizuho cut its outlook, amid continued fallout from a fatal roller-coaster accident, precautionary ride closures, and fresh safety concerns. Bears worry about reputational damage, legal exposure, and the companys debt, while some traders view the selloff as overdone and point to short-squeeze potential.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD is drawing attention after its latest earnings report showed a revenue decline but improved profitability and cash flow, yet shares sold off sharply. Traders are debating whether the drop is an overreaction to otherwise solid results or reflects weak Chinese consumer demand and persistent pressure on the companys growth.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEP is drawing attention amid a steep selloff and concerns about potential hedging losses, debt maturities, and whether its distribution is sustainable ahead of earnings. Holders are frustrated by Icahns limited communication, while some bullish traders point to IEPs CVR Energy stake and speculate about a short squeeze or a rebound.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds quarterly earnings miss and sharply lower fourth-quarter profit guidance, driven by elevated fuel costs, are prompting debate as shares rally despite the weak outlook. Traders are weighing margin pressure against record revenue, resilient travel demand and expectations for continued revenue growth.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of an FDA decision on deramiocel for Duchenne muscular dystrophy, particularly the narrowed application focused on upper-limb function and the HOPE-3 data. Traders are divided: some see a path to approval, while others cite the prior advisory committee vote and disputed statistical analyses as risks; the uncertainty is fueling volatile trading and speculation about short-selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics

(RTTNews) - Sentynl Therapeutics, Inc., a unit of Zydus Lifesciences Limited, on Tuesday said it has entered into an option and license agreement with Mereo BioPharma Group plc (MREO) for U.S. commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Defici...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million.
Organigram Global (NASDAQ:OGI)read more...

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)

Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin...

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO) Receives Consensus Rating of "Hold" from Analysts

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Get Free Report) has been given a consensus rating of "Hold" by the eight ratings firms that are presently covering the company, Marketbeat...

MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Mereo BioPharma Group plc (Mereo BioPharma or the Company) (NASDAQ: MREO) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class...

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO

Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS...

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm

MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud...

MREO Deadline: Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100Kto Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of American Depositary Shares (ADS) of Mereo BioPharma Group plc (NASDAQ...

MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026

MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026 MREO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi...

DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026

DEADLINE APPROACHING: Berger Montague Advises BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026 DEADLINE APPROACHING: Berger Montague...

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Mereo Biopharma Group Plc - ADR

Why Did RARE Stock Plunge Over 41% Today?

Equity

Extremely Bearish Sentiment

<ul class="summary-bullets"><li>The company said that results from the Phase 3 Orbit and Cosmic studies for an experimental drug designed to help people with brittle bone disease did not significantly reduce annualized clinical fracture rates.</li><li>Both studies showed improvements in bone mineral density, the company said.&nbsp;</li><li>Ultragenyx also noted that it will reduce expenses significantly after evaluating its planned operations.</li></ul>Ultragenyx Pharmaceutical Inc. (RARE) shares plunged over 41% on Monday after the company announced disappointing results from its Phase 3 studies for its experimental drug designed to help people with brittle bone disease.The company said that results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI), conducted in partnership with Mereo Biopharma (MREO), did not significantly reduce annualized clinical fracture rates compared to placebo or bisphosphonates, respectively. However, both studies showed improvements in bone mineral density, the company said.The firm also said it will significantly reduce expenses after evaluating its planned operations.<h2 class="st-heading-2">Trial Details</h2>In the Orbit study, participants showed substantial improvements in bone mineral density compared with the placebo group. However, that did not result in a significant reduction in annualized fracture rates, since the placebo group also had a low fracture rate, the company noted.In the Cosmic study, which included pediatric patients, the baseline fracture rate was substantially higher than in the Orbit patient group. While the study showed improvements in bone mineral density and a reduction in annualized fracture rate compared to bisphosphonate-treated patients, the results were not statistically significant.“We are surprised and disappointed by these results given the promising data from our Phase 2 study and the lack of approved treatment options available to patients with OI who live with significant pain, disability, and disease burden,” said Emil Kakkis, chief executive officer and president of Ultragenyx. “We continue to explore the data to gain deeper understanding of the findings.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RARE">RARE shares</a> jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. The stock was also among the top trending tickets on the platform.<figure class="image"><img style="aspect-ratio:1283/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_9_02_19_PM_png_233d427277.webp" alt="On Stocktwits, retail sentiment around RARE shares jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. " width="1283" height="153"></figure>Shares of RARE are down over 51% in the past year.Editor's Note: The story has been updated to reflect that the Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta was conducted in partnership with Mereo Biopharma.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program. 

iShares ESG Aware 60/40 Balanced Allocation ETF

JPMorgan Healthcare Leaders ETF

Mereo Biopharma

Ultragenyx Pharmaceutical Inc

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

Meta ($META) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$0.2933
Prev Close	$0.2951
Open	$0.3012
Dividend Yield	0.00%
50-Day Moving Average	$0.3084
Beta	1.57
Avg. Volume	1.91M
PE Ratio	-1.68

52-Week High	$2.37
52-Week Low	$0.20
Market Capitalization	$47.1M
EPS (Annual)	-$0.2633
Price to Book	1.64
Revenue Per Employee	$12,850.46

Feed

News

Sentiment

Earnings

Fundamentals

Info

MREO Fundamentals